D osing of warfarin has long been problematic, especially at therapy initiation. [1] [2] [3] [4] [5] Since an apparent replacement for warfarin therapy is not in sight, other methods of decreasing this medication's potential dangers are being pursued. One of these methods is the use of genetic phenotyping, prior to the initiation of therapy, to help predict the starting dose of warfarin for each patient.
Two key genetic factors influence a patient's sensitivity to warfarin therapy; the activity of CYP2C9 and the enzyme vitamin K epoxide reductase (VKOR). The CYP2C9 is responsible for the metabolizing the active and more potent S-enantiomer of warfarin to inactive metabolites. VKOR is the enzyme that is responsible for the synthesis of vitamin K dependent clotting factors that are inhibited by warfarin; 1-8 however, the variability in the maintenance dose of warfarin is probably most influenced by CYP2C9 activity. It is estimated that 10% to 20% of the variability in warfarin dose is a function of the patient's CYP2C9 genotype, while 29% to 39% of the variability is influenced by the CYP2C9 genotype in combination with other patient factors (eg, age, body surface area, sex, and concomitant drug use). 8, 9 One of the tests being promoted to assist in the dosing of war-farin is made by Genelex. This test is designed to measure both the CYP2C9 and VKORC1 gene from a buccal swab sample. The interest in this type of testing has recently increased with the addition of a black box warning to the warfarin label regarding bleeding risk and the initiation of Genelex's direct to consumer advertising campaign. 10, 11 The new black box warning stresses that warfarin therapy can be associated with major or fatal bleeding, and the risk of bleeding is increased during the starting period and with higher doses. 10 Genelex uses an algorithm to apply the results from the patient's CYP2C9 and VKORC1 genotype assessment, along with their age and height information to formulate an individualized dosing recommendation. 11, 12 One of the key problems with this test is the turn around time from the acquisition of the sample to the availability of test results. Genelex's Web site indicates a 4 day turn around time for the results. 11, 12 In clinical practice, we do not always have 4 days to wait for the initiation of warfarin therapy, if the duration of hospitalization is going to be decreased. Even with a more accurate prediction of the target dose for warfarin, it will take 4 to 5 days to achieve a stable dose in patients classified as normal metabolizers (CYP2C9 genotype *1/*1), 8 to 10 days in patients classified as intermediate metabolizers (CYP2C9 genotype *1/*2), and 12 to 15 days in patients classified as intermediate to poor metabolizers (CYP2C9 genotype *1/*3, *2/*2, *3/*3), 7, 12 but this type of information should help tailor the therapy to the needs of the individual patients and decrease the risk of bleeding.
A combined clinical and costeffectiveness trial that compares the initiation of therapy using this type of testing in conjunction with a team-run anticoagulation service versus a team-run anticoagulation service alone, and not a direct to consumer advertising campaign, is what is really needed prior to the wide spread adoption of this type of testing. Until this type of headto-head comparison is conducted, we can only hope that this type of information, when used appropriately, can decrease the risk of bleeding during the initiation of warfarin therapy in higher risk patients and not be used for all patients requiring warfarin therapy.
